Bionano Genomics (BNGO) Accounts Payables (2017 - 2026)

Bionano Genomics has disclosed Accounts Payables across 10 years of filings, most recently posting $5.1 million for Q1 2026.

• Accounts Payables for Q1 2026 came in at $5.1 million, down 22.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.1 million (down 22.86% YoY), and the FY2025 annual result was $5.6 million, down 19.71% from the prior year.
• Accounts Payables came in at $5.1 million for Q1 2026 at Bionano Genomics, down from $5.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $15.8 million in Q1 2023 to a low of $5.1 million in Q1 2026.
• The 5-year median for Accounts Payables is $8.7 million (2024), against an average of $9.0 million.
• Across the five-year window, Accounts Payables soared 198.33% in 2022 and slumped 43.39% in 2024, its largest moves.
• Bionano Genomics' Accounts Payables stood at $12.5 million in 2022, then declined by 17.15% to $10.4 million in 2023, then slumped by 32.95% to $7.0 million in 2024, then slipped by 19.71% to $5.6 million in 2025, then decreased by 9.45% to $5.1 million in 2026.
• The last three Accounts Payables figures came in at $5.1 million (Q1 2026), $5.6 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.